balugrastim
Recombinant proteinexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT01940601)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
CSF3R agonist
Long-acting granulocyte colony-stimulating factor (G-CSF) composed of a genetic fusion between recombinant human serum albumin and G-CSF.
- Granulocyte colony-stimulating factorSupplementation
CSF3 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108572 ↗
Also known as
- balugrastim
- balugrastim
- balugrastim
- cg-10639
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01940601 | Phase 2 | Sep 1, 2014 | Teva |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1